Name | Date | Type | Actions |
---|---|---|---|
First nine months 2022 sales: €405M In line with year-end outlook |
Public releases | ||
2022 HALF YEAR RESULTS Additional information on the Group’s strategy Following the conference call organised on 15 September 2022 to present its half-year results, Vetoquinol would like to provide some additional information on the strategy implemented and its outlook. |
Public releases , Half Year Report | ||
2022 HALF YEAR RESULTS Sales: €271m (up 6.0% as reported) |
Public releases | ||
H1 2022 Sales H1 2022 Sales: €271m, up 6.1% |
Public releases | ||
Availability of the 2021 universal registration document Vetoquinol informs that it has filed its 2021 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 22th, 2022. |
Public releases | ||
Q1 2022 SALES: €135M Q1 2022 SALES: €135M |
Public releases | ||
2021 Annual results ALL FINANCIAL INDICATORS UP. |
Public releases | ||
Double-digit growth in 2021 Total Group Sales: €521 million (up 21.9% as reported) |
Public releases | ||
Vétoquinol continues to launch reference products Lure (France), December 16, 2013 – In line with its strategy of developing products targeting fast-growing markets, the Vétoquinol Group expands its Flexadin® range world-wide and launches Zylkène® in the United States. |
Public releases | ||
2013 3rd quarter sales show organic growth Vétoquinol generated sales of €74.0 million in the 3rd quarter of 2013, a drop of 0.1% based on reported data, and a 4.4% increase at constant exchange rates. |
Public releases |